GlassScriptPhysician profile
Hyatt Peter Degreen
NPI 1497742183
$1,300.26
in general payments reported to CMS, 2019-2025
29 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $67.01 · 2021: $190 · 2022: $234 · 2023: $167 · 2024: $124 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $218.53 | 2025 | Rybrevant, Carvykti |
| Gilead Sciences, INC. | $169.35 | 2022-2024 | Trodelvy |
| Myovant Sciences INC. | $98.50 | 2021 | |
| Pfizer INC. | $82.46 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $77.96 | 2020-2024 | Enhertu |
| Seagen INC. | $55.56 | 2019-2022 | |
| Spectrum Pharmaceuticals INC. | $55.12 | 2025 | Rolvedon |
| Kite Pharma, INC. | $50.79 | 2020-2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $48.86 | 2021-2023 | |
| Blueprint Medicines Corporation | $47.86 | 2023 | Ayvakit |
| Immunocore Limited | $41.06 | 2025 | Kimmtrak |
| Janssen Scientific Affairs, LLC | $35.65 | 2019 | |
| Lilly USA, LLC | $34.03 | 2023 | Verzenio, Retevmo, Jaypirca |
| Adc Therapeutics America, INC. | $25.64 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.32 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $24.05 | 2022 | |
| Daiichi Sankyo INC. | $21.26 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.81 | 2019 | |
| Morphosys, US INC. | $19.66 | 2022 | |
| Merck Sharp & Dohme LLC | $18.53 | 2019 | |
| Genzyme Corporation | $18.38 | 2021 | |
| Aveo Pharmaceuticals, INC. | $17.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.08 | 2019 | |
| Emd Serono, INC. | $14.81 | 2020 | |
| Eisai INC. | $13.93 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.22 | 2020 | |
| Array Biopharma INC | $12.82 | 2019 | |
| Celgene Corporation | $12.56 | 2022 | |
| Exelixis INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyatt Degreen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.